This is a phase 1 study in which healthy adult volunteers will receive BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
17
Investigative Site
Beijing, Beijing Municipality, China
Incidence of adverse events (AEs) by CTCAE v5.0
Time frame: up to 24 weeks
Proportion of subjects with SAEs
Time frame: up to 24 weeks
Proportion of subjects with infusion-related reactions
Time frame: up to 24 weeks
Proportion of subjects with hypersensitivity reactions
Time frame: up to 24 weeks
Serum Concentration of BRII-198
Time frame: up to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.